8-K current report · filed Aug 4, 2026

Syndax Pharmaceuticals Inc (SNDX) 8-K Current Report: August 4, 2026

Item EX-99.1Item EX-99.2Item 2.02SNDX overview

Short answer

Syndax Pharmaceuticals Inc (SNDX) filed an 8-K current report with the SEC on August 4, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 2.02 (Results of Operations and Financial Condition). Syndax reported financial results for the quarter and year ended June 30, 2026.

Syndax Pharmaceuticals Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Syndax reported financial results for the quarter and year ended June 30, 2026
  • Press release and investor presentation furnished as Exhibits 99.1 and 99.2
  • Investor focus: detailed results, cash position and outlook require review of the referenced exhibits

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $72.8M, up 92% year over year, driven by Revuforj product revenue $54.7M and Niktimvo collaboration revenue $18.1M
  • Revuforj prescriptions approximately 1,500, up 121% year over year, supporting continued menin-inhibitor demand and longer treatment duration
  • Niktimvo net revenue $60.3M, up 67% year over year, with Syndax’s profit-share contribution rising 9% sequentially to $18.1M
  • Cash, equivalents, and investments $575.1M; 2026 operating-expense guidance approximately $400M excluding $50M stock compensation
  • Key catalysts: axatilimab IPF and frontline cGVHD data expected in 4Q26, alongside expanded EGFR and myelofibrosis pipeline development

Item EX-99.2 · Exhibit EX-99.2

  • 2Q26 revenue $72.8M, up 92% year over year, led by Revuforj product revenue $54.7M and Niktimvo collaboration revenue $18.1M
  • Revuforj revenue growth 91% year over year, with approximately 1,500 prescriptions and increasing post-transplant treatment duration
  • Niktimvo generated $60.3M partner net revenue, up 67% year over year, producing Syndax collaboration revenue of $18.1M
  • Cash and equivalents $575.1M, supporting stated 2026 R&D and SG&A expense guidance of $400M plus $50M stock-option expense
  • Key catalysts: Phase 2 axatilimab data in IPF and frontline cGVHD targeted for 4Q26, plus EGFR inhibitor IND submission by year-end 2026

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Syndax Pharmaceuticals Inc 8-K filings

Get the next SNDX 8-K as it lands

Follow SNDX for push alerts, or ask the research agent what this filing means.